Janux Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.12.24	Navigating 10 Analyst Ratings For Janux Therapeutics (Benzinga)
05.12.24	Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants (Businesswire)
05.12.24	Why Janux Therapeutics Crushed the Market Today (MotleyFool)
03.12.24	MÄRKTE USA/Gut behauptet - Zinssenkungserwartung steigt wieder (Dow Jones)
03.12.24	Janux Therapeutics Announces Proposed Public Offering (Businesswire)
03.12.24	MÄRKTE USA/Verschnaufpause - US Steel leiden unter Trump-Kommentar (Dow Jones)
03.12.24	AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday (Benzinga)
25.11.24	Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies (Businesswire)
22.11.24	Evaluating Janux Therapeutics: Insights From 6 Financial Analysts (Benzinga)
06.11.24	Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (Businesswire)
24.10.24	Cracking The Code: Understanding Analyst Reviews For Janux Therapeutics (Benzinga)
06.09.24	Navigating 5 Analyst Ratings For Janux Therapeutics (Benzinga)
07.08.24	Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (Businesswire)
22.07.24	Janux Therapeutics Announces Updates to Board of Directors (Businesswire)
30.05.24	The Latest Analyst Ratings For Janux Therapeutics (Benzinga)
13.05.24	Analyst Ratings For Janux Therapeutics (Benzinga)
07.05.24	Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (Businesswire)
16.04.24	A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts (Benzinga)
12.04.24	Why Janux Therapeutics Stock Is Crushing It This Week (MotleyFool)
11.04.24	Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday? (Benzinga)
11.04.24	Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday? (Benzinga)
11.04.24	Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday (Benzinga)
11.04.24	Why Janux Therapeutics Stock Soared as the Market Sagged Today (MotleyFool)
20.03.24	Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst (Benzinga)
20.03.24	Forecasting The Future: 4 Analyst Projections For Janux Therapeutics (Benzinga)
13.03.24	B of A Securities Maintains Buy Rating for Janux Therapeutics: Here's What You Need To Know (Benzinga)
08.03.24	Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Businesswire)
02.03.24	After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy? (MotleyFool)
29.02.24	Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants (Businesswire)
27.02.24	Janux Therapeutics Announces Proposed Public Offering of Common Stock (Businesswire)
27.02.24	Janux Therapeutics-Aktie geht durch die Decke: Positive klinische Daten treiben an (finanzen.ch) Am Dienstag rückt am US-Aktienmarkt mit Janux Therapeutics ein kleines Unternehmen mit einer grossen Aktienbewegung in den Fokus der Anleger.» mehr
27.02.24	Cancer-Focused Janux Therapeutics Stock Remains Undervalued Despite Price Surge After Study Data: Analyst (Benzinga)
26.02.24	Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors (Businesswire)
20.02.24	Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 (Businesswire)
08.01.24	Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer (Businesswire)
07.11.23	Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (Businesswire)
08.08.23	Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (Businesswire)
17.07.23	Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Businesswire)
17.07.23	Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	76.62	0.39 %	K V
Part Grp Hldg	1’271.50	0.36 %	K V
Holcim	89.08	0.25 %	K V
Logitech Intl	74.82	-0.05 %	K V
Lonza Grp	540.60	-0.15 %	K V
UBS Group	27.82	-1.24 %	K V
Sika	223.10	-1.37 %	K V
Nestle	74.10	-1.49 %	K V
Swiss Re	129.60	-1.78 %	K V
Givaudan	3’961.00	-2.46 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Janux Therapeutics Inc Registered Shs

Aktien Top/Flop

Janux Therapeutics Peer Group Nachrichten

Meistgelesene Nachrichten